Comparative Pharmacology
Head-to-head clinical analysis: CAPOZIDE 50 15 versus ZESTRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CAPOZIDE 50 15 versus ZESTRIL.
CAPOZIDE 50/15 vs ZESTRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CAPOZIDE 50/15 combines captopril (angiotensin-converting enzyme inhibitor) and hydrochlorothiazide (thiazide diuretic). Captopril inhibits ACE, reducing angiotensin II formation, decreasing aldosterone secretion, and lowering blood pressure. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- cotransporter in distal convoluted tubules.
Lisinopril competes with angiotensin I for binding to angiotensin-converting enzyme (ACE), inhibiting its activity, thereby preventing conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. This leads to decreased blood pressure, reduced aldosterone secretion, and decreased sodium and water retention.
Oral, 1 tablet (captopril 50 mg / hydrochlorothiazide 15 mg) once daily. May increase to 2 tablets daily in divided doses if needed.
10 mg orally once daily initially; titrate to 20-40 mg orally once daily. Maximum 80 mg/day.
None Documented
None Documented
Captopril: terminal half-life ~2 hours (in patients with normal renal function; prolonged in renal impairment to 21-36 hours). Hydrochlorothiazide: half-life 6-15 hours (mean ~9 hours; prolonged in renal impairment). Clinical context: dosing interval affected by renal function.
Terminal elimination half-life is about 12 hours for lisinopril; in heart failure, half-life may be prolonged. Steady-state achieved in 2-3 days.
Captopril: renal excretion of unchanged drug and metabolites, primarily in urine (60-75%), with ~20% as unchanged captopril; small amount in feces (5-10%). Hydrochlorothiazide: renal excretion (95% unchanged), <5% via biliary/fecal.
Primarily renal (approximately 70% unchanged), with the remainder excreted as inactive metabolites via feces and urine.
Category C
Category C
ACE Inhibitor and Diuretic Combination
ACE Inhibitor